US Patent Issued to GUANGZHOU SINOGEN PHARMACEUTICAL on Nov. 25 for "Use of genetically engineered strain VNP20009-M in preventing and treating cancer metastasis" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,664, issued on Nov. 25, was assigned to GUANGZHOU SINOGEN PHARMACEUTICAL Co. LTD. (Guangzhou, China).

"Use of genetically engineered strain VNP20009-M in preventing and treating cancer metastasis" was invented by Allan Zijian Zhao (Nanjing, China), Sujin Zhou (Nanjing, China), Yan Lin (Nanjing, China), Zhenggang Zhao (Nanjing, China) and Fanghong Li (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides uses of genetically engineered attenuated Salmonella typhimurium strain VNP20009-M in preventing and treating cancer metastasis. The genetically engineered strain VNP20009-M is targeted to cancer cells and has ...